File:Structure of ADC.png

Structure of Belantamab mafodotin, an antibody-drug conjugate (ADC) used for treatment-resistant multiple myeloma. An IgG1 monoclonal antibody (mAb) targeting B-cell maturation antigen (BCMA) expressed on multiple myeloma cells is linked to the cytoxic payload monomethyl auristatin F (MMAF), a microtuble disrupter.

Modified figure reprinted with permission from Farooq, A.V., Degli Esposti, S., Popat, R. et al. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmol Ther (2020). https://doi.org/10.1007/s40123-020-00280-8. Copyright Springer Nature.